Clovis Oncology (CLVS) Rating Reiterated by Gabelli

Clovis Oncology (NASDAQ:CLVS)‘s stock had its “buy” rating restated by stock analysts at Gabelli in a report released on Tuesday.

CLVS has been the subject of a number of other reports. Piper Jaffray Companies dropped their target price on shares of Clovis Oncology to $18.00 and set a “neutral” rating for the company in a report on Wednesday, October 31st. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Clovis Oncology in a report on Tuesday, October 2nd. BidaskClub cut shares of Clovis Oncology from a “sell” rating to a “strong sell” rating in a report on Wednesday, October 24th. Guggenheim began coverage on shares of Clovis Oncology in a report on Monday, September 17th. They issued a “buy” rating for the company. Finally, reaffirmed a “hold” rating on shares of Clovis Oncology in a report on Tuesday, October 2nd. Three analysts have rated the stock with a sell rating, four have assigned a hold rating and ten have given a buy rating to the company’s stock. Clovis Oncology has an average rating of “Hold” and a consensus target price of $56.32.

NASDAQ CLVS opened at $20.80 on Tuesday. The stock has a market cap of $1.13 billion, a P/E ratio of -4.06 and a beta of 2.12. Clovis Oncology has a 52-week low of $11.50 and a 52-week high of $69.02. The company has a debt-to-equity ratio of 2.46, a current ratio of 9.03 and a quick ratio of 8.46.

Clovis Oncology (NASDAQ:CLVS) last posted its quarterly earnings results on Tuesday, October 30th. The biopharmaceutical company reported ($1.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.60) by ($0.11). Clovis Oncology had a negative return on equity of 108.92% and a negative net margin of 390.65%. The firm had revenue of $22.76 million for the quarter, compared to analysts’ expectations of $30.11 million. During the same period in the prior year, the company earned ($1.24) earnings per share. The company’s revenue for the quarter was up 35.4% on a year-over-year basis. As a group, sell-side analysts predict that Clovis Oncology will post -6.8 EPS for the current fiscal year.

Institutional investors have recently modified their holdings of the business. Bank of Montreal Can grew its position in shares of Clovis Oncology by 2,420.9% in the second quarter. Bank of Montreal Can now owns 15,831 shares of the biopharmaceutical company’s stock valued at $720,000 after purchasing an additional 15,203 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. grew its position in shares of Clovis Oncology by 39.1% in the second quarter. Los Angeles Capital Management & Equity Research Inc. now owns 49,849 shares of the biopharmaceutical company’s stock valued at $2,267,000 after purchasing an additional 14,025 shares during the last quarter. KBC Group NV grew its position in shares of Clovis Oncology by 6.1% in the second quarter. KBC Group NV now owns 93,502 shares of the biopharmaceutical company’s stock valued at $4,251,000 after purchasing an additional 5,339 shares during the last quarter. State of Wisconsin Investment Board grew its position in shares of Clovis Oncology by 12.5% in the second quarter. State of Wisconsin Investment Board now owns 48,482 shares of the biopharmaceutical company’s stock valued at $2,204,000 after purchasing an additional 5,400 shares during the last quarter. Finally, Rhumbline Advisers grew its position in shares of Clovis Oncology by 9.5% in the second quarter. Rhumbline Advisers now owns 47,586 shares of the biopharmaceutical company’s stock valued at $2,164,000 after purchasing an additional 4,110 shares during the last quarter.

Clovis Oncology Company Profile

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.

Featured Article: The Role of a Fiduciary and Individual Investors

Analyst Recommendations for Clovis Oncology (NASDAQ:CLVS)

Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply